ArticleOncotarget2019
Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- [Vascular neoplasms of the liver].Pathologie (Heidelberg, Germany) · 2025Article
- Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations.Molecular cancer therapeutics · 2025Article
- A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review.Diagnostic pathology · 2023Review
- NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.Cancer discovery · 2023Article
- Review
- Discovery and functional characterization of the oncogenicity and targetability of a novelCold Spring Harbor molecular case studies · 2022Article
- Pediatric vascular tumors of the liver: Review from the pathologist's point of view.World journal of hepatology · 2021Review
- GOPC-ROS1 mosaicism in agminated Spitz naevi: report of two cases.Virchows Archiv : an international journal of pathology · 2021Article
- Primary cardiac angiosarcoma directly invading the right lung: An autopsy report.Clinical case reports · 2021Article
- Primary malignant vascular tumors of the liver in children: Angiosarcoma and epithelioid hemangioendothelioma.World journal of gastrointestinal oncology · 2021Review
- New insights into the pathophysiology and clinical care of rare primary liver cancers.JHEP reports : innovation in hepatology · 2021Review
- Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis.Histology and histopathology · 2021Review
- A Catalog of 5' Fusion Partners inJTO clinical and research reports · 2020Review
- Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring aNeuro-oncology advancesArticle
- Hepatic Angiosarcoma: Clinicopathologic Study With an Investigation of ROS1 Gene Rearrangements.In vivo (Athens, Greece)Article
- A NovelPediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic angiosarcoma (HAS) is a rare and highly lethal malignancy with few effective systemic treatments. Relatively little is known about the genetic abnormalities that drive this disease. As a result, there has been minimal progress towards applying targeted therapies to the treatment of HAS. We describe the first reported case of a patient with HAS that harbored a fusion of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.